Eris Lifesciences has formally notified the stock exchanges about its upcoming board meeting scheduled for February 13, 2026. The meeting will focus on reviewing and approving the company's quarterly financial performance for the third quarter of fiscal year 2026.

Board Meeting Details

The pharmaceutical company's Board of Directors will convene to consider and approve both standalone and consolidated unaudited financial results. The meeting will cover the financial performance for two key periods:

Trading Window Restrictions

Eris Lifesciences has implemented trading window restrictions in accordance with regulatory requirements. The company had previously informed stakeholders about these measures through its communication dated December 29, 2025.

Regulatory Compliance

The trading window closure aligns with the company's internal policy on 'Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company'. This measure ensures compliance with SEBI's insider trading regulations and maintains market integrity during the financial results announcement period.

Corporate Communication

The official notification was signed by Milind Talegaonkar, Company Secretary & Compliance Officer, and submitted to both BSE Limited and National Stock Exchange of India Limited. The company trades under security code 540596 on BSE and under the symbol ERIS on NSE.

Investors and stakeholders will need to wait until the board meeting concludes and results are officially declared before normal trading activities can resume for designated persons associated with the company.

Eris Lifesciences Limited has successfully completed its strategic acquisition of Swiss Parenterals Limited, transforming the subsidiary into a wholly-owned entity through a preferential share allotment completed on January 16, 2026. The pharmaceutical company's Executive Committee approved the allotment of equity shares in exchange for the remaining 30% stake in Swiss Parenterals.

Share Allotment Details

The Executive Committee of Eris Lifesciences' Board approved the allotment of significant equity shares to complete the acquisition:

The allotment was made on a preferential basis through private placement to Mr. Naishadh Shah in exchange for his 16,74,493 equity shares of Swiss Parenterals Limited, representing the remaining 30% stake in the subsidiary.

Capital Structure Impact

The share allotment has resulted in changes to Eris Lifesciences' capital structure:

Regulatory Compliance and Approvals

The transaction was executed following comprehensive regulatory compliance. The company received in-principle approval from both NSE and BSE on January 9, 2026, for the preferential issue. The process began with the board meeting held on November 24, 2025, followed by shareholder approval through postal ballot on December 24, 2025.

The allotment complies with provisions of the Companies Act, 2013, SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The newly allotted shares will rank pari-passu with existing equity shares, subject to lock-in restrictions under SEBI ICDR Regulations.

Strategic Implications

With the completion of this acquisition, Swiss Parenterals Limited has become a wholly-owned subsidiary of Eris Lifesciences. This strategic move provides the company with enhanced control over Swiss Parenterals' operations and potential operational synergies. The subscription shares will be listed on NSE and BSE upon receipt of relevant listing approvals and will be subject to lock-in provisions as specified under Chapter V of the SEBI ICDR Regulations.